Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-592 mimic is a synthetic RNA-based therapeutic designed to replicate the function of the endogenous tumor suppressor microRNA-592 (miR-592). In various malignancies, including epithelial ovarian cancer, miR-592 expression is frequently downregulated, contributing to tumor progression. The mimic functions by binding to the 3' untranslated region (UTR) of specific target messenger RNAs, most notably the ERBB3 (Her3) oncogene. This binding leads to the degradation of the mRNA or the inhibition of its translation, thereby reducing the levels of the ERBB3 protein. By downregulating ERBB3, the microRNA-592 mimic inhibits critical signaling pathways involved in cell proliferation, migration, and invasion. Preclinical research has demonstrated that exogenous administration of this mimic can suppress tumor growth in mouse xenograft models, suggesting its potential as a novel therapeutic strategy for cancers where miR-592 is lost.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microRNA-592 mimic.